Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells

Archive ouverte

Valinciute, Gintvile | Ecker, Jonas | Selt, Florian | Hielscher, Thomas | Sigaud, Romain | Ridinger, Johannes | Thatikonda, Venu | Gatzweiler, Charlotte | Robinson, Sarah | Talbot, Julie | Bernardi, Flavia | Picard, Daniel | Blattner-Johnson, Mirjam | Schmid, Simone | Jones, David, T | van Tilburg, Cornelis, M | Capper, David | Kool, Marcel | Remke, Marc | Oehme, Ina | Pfister, Stefan, M | Roussel, Martine, F | Ayrault, Olivier | Witt, Olaf | Milde, Till

Edité par CCSD ; Springer Verlag -

International audience. Purpose We and others have demonstrated that MYC-amplified medulloblastoma (MB) cells are susceptible to class I histone deacetylase inhibitor (HDACi) treatment. However, single drug treatment with HDACi has shown limited clinical efficacy. We hypothesized that addition of a second compound acting synergistically with HDACi may enhance efficacy. Methods We used a gene expression dataset to identify PLK1 as a second target in MB cells and validated the relevance of PLK1 in MB. We measured cell metabolic activity, viability, and cycle progression in MB cells after treatment with PLK1-specific inhibitors (PLK1i). Chou-Talalay synergy calculations were used to determine the nature of class I HDACi entinostat and PLK1i interaction which was validated. Finally, the clinical potential of the combination was assessed in the in vivo experiment. Results MYC-amplified tumor cells are highly sensitive towards treatment with ATP-competitive PLK1i as a monotherapy. Entinostat and PLK1i in combination act synergistically in MYC-driven MB cells, exerting cytotoxic effects at clinically relevant concentrations. The downstream effect is exerted via MYC-related pathways, pointing out the potential of MYC amplification as a clinically feasible predictive biomarker for patient selection. While entinostat significantly extended survival of mice implanted with orthotopic MYC-amplified MB PDX, there was no evidence of the improvement of survival when treating the animals with the combination. Conclusion The combination of entinostat and PLK1i showed synergistic interaction in vitro, but not in vivo. Therefore, further screening of blood-brain barrier penetrating PLK1i is warranted to determine the true potential of the combination as no on-target activity was observed after PLK1i volasertib treatment in vivo.

Suggestions

Du même auteur

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

Archive ouverte | Kocher, Daniela | CCSD

International audience. Abstract Introduction Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, ra...

The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors

Archive ouverte | Bartl, Jasmin | CCSD

International audience. Most lncRNAs display species-specific expression patterns suggesting that animal models of cancer may only incompletely recapitulate the regulatory crosstalk between lncRNAs and oncogenic pat...

Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome

Archive ouverte | Kolodziejczak, Anna | CCSD

International audience. Abstract Background The prognosis for Li–Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the dev...

Chargement des enrichissements...